{
    "title": "114_s3335",
    "content": "The \"Fair Accountability and Innovative Research Drug Pricing Act of 2016\" requires reporting on justification for drug price increases under Title III of the Public Health Service Act. The \"Fair Accountability and Innovative Research Drug Pricing Act of 2016\" defines key terms such as average manufacturer price, manufacturer, and qualifying drug. The Act requires reporting on drug price increases under Title III of the Public Health Service Act. The \"Fair Accountability and Innovative Research Drug Pricing Act of 2016\" defines qualifying drugs as those subject to specific regulations and not designated for rare diseases or as vaccines, with a portion of sales to Medicare beneficiaries. The manufacturer of a qualifying drug must report any price increase of 10 percent or more over a 12-month period to the Secretary at least 30 days before the planned effective date. The report should include details about the drug. The manufacturer of a qualifying drug must report any price increase of 10 percent or more over a 12-month period to the Secretary at least 30 days before the planned effective date. The report should include details about the drug, such as the percentage increase in price, justifications for previous price increases, the initial developer of the drug, and the history of price increases since approval. The manufacturer must report price increases of 10% or more for a qualifying drug to the Secretary 30 days before the effective date. The report should include details like the drug's list price, total expenditures on materials, manufacturing, patents, and licensing, percentage of research and development expenditures from Federal funds, and total research and development expenditures for basic, preclinical, and clinical research. The manufacturer must report revenue and profit generated from a qualifying drug each year since its approval under the Federal Food, Drug, and Cosmetic Act. This includes revenue from clinical research, new drug development, expanded indications, and postmarket requirements. The manufacturer must report total revenue, net profit, marketing costs, and advertising expenses for the qualifying drug. Additionally, they need to disclose spending on dividends, stock repurchases, executive compensation metrics, and any other relevant financial information. Manufacturers of qualifying drugs must report total revenue, net profit, marketing costs, and advertising expenses. They also need to provide information on drug research and development expenditures, clinical trials on unsuccessful drugs, and any other relevant details as deemed appropriate by the Secretary. Failure to submit a required report may result in a civil penalty of $100,000 per day. Compliance determinations regarding report submissions are made by the Secretary. The Inspector General of the Department of Health and Human Services annually reviews average manufacturer price information for compliance. The Secretary must post reports on the department's website within 30 days of submission, consulting stakeholders for feedback on content and format. The Secretary must ensure that public reports are user-friendly and written in plain language. Confidential commercial information and trade secrets must be protected. The Secretary will use collected civil penalties to fund activities for drug value and price transparency. Annual reports to Congress are required. The Secretary will submit an annual report to Congress summarizing information from section 399OO, including reports and economic analyses, while protecting trade secrets and confidential information."
}